Business
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CALIFORNIA / ACCESS
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / March 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or \"the Company\") today issued a reminder that today, March 2, 2026, is the Record Date for the Company's one-time special stock dividend (the \"Special Stock Dividend\"). As announced, in February 2026 Jaguar's Board of Directors declared a one-time Special Stock Dividend to holders of Jaguar Common Stock and certain outstanding warrants as of record on March 2, 2026. The Special Stock Dividend will consist of the Company's Series O Convertible Preferred Stock (the \"Preferred Stock\").The payment date for the Special Stock Dividend is March 4, 2026, two days after the Record Date. The dividend will be sent to eligible holders of Jaguar Common Stock and certain outstanding warrants automatically, with no action required by the eligible parties.\"Jaguar is issuing the Special Stock Dividend to reward and recognize our passionate and supportive stockholders and provide protection against potential dilution as we explore pathways to repay and restructure our existing indebtedness,\" said Lisa Conte, Jaguar's founder, president, and CEO. \"Jaguar has a sharp strategic focus on our ongoing global development program for our crofelemer powder-for-oral-solution formulation for intestinal failure. As announced, Jaguar was provided with meaningful non-dilutive capital in January 2026 upon entering a U.S. license agreement with Future Pak for Mytesi® - an agreement that is fully aligned with our strategy to concentrate Jaguar's crofelemer development efforts on human rare-disease intestinal failure indications.\"The Preferred Stock is not transferable and will not be listed for trading on any stock exchange and will not trade with the Common Stock. For additional information about the Special Stock Dividend and terms of the Preferred Stock and associated risk factors, please refer to the Form 8-K the Company filed with the U.S. Securities and Exchange Commission on February 18, 2026, which can be viewed on the Company's website by clicking here.About CrofelemerCrofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as \"dragon's blood,\" of the Croton lechle...